- Home
- DRRX vs MIRM Comparison
DRRX vs MIRM Comparison
Compare DRRX & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRRX
- MIRM
- Stock Information
- Founded
- DRRX 1998
- MIRM 2018
- Country
- DRRX United States
- MIRM United States
- Employees
- DRRX N/A
- MIRM N/A
- Industry
- DRRX Biotechnology: Pharmaceutical Preparations
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- DRRX Health Care
- MIRM Health Care
- Exchange
- DRRX Nasdaq
- MIRM Nasdaq
- Market Cap
- DRRX N/A
- MIRM 2.5B
- IPO Year
- DRRX 2000
- MIRM 2019
- Fundamental
- Price
- DRRX $0.67
- MIRM $49.09
- Analyst Decision
- DRRX Hold
- MIRM Strong Buy
- Analyst Count
- DRRX 1
- MIRM 9
- Target Price
- DRRX N/A
- MIRM $66.22
- AVG Volume (30 Days)
- DRRX 43.2K
- MIRM 449.1K
- Earning Date
- DRRX 08-12-2025
- MIRM 08-06-2025
- Dividend Yield
- DRRX N/A
- MIRM N/A
- EPS Growth
- DRRX N/A
- MIRM N/A
- EPS
- DRRX N/A
- MIRM N/A
- Revenue
- DRRX $1,856,000.00
- MIRM $379,251,000.00
- Revenue This Year
- DRRX N/A
- MIRM $35.83
- Revenue Next Year
- DRRX $673.00
- MIRM $16.83
- P/E Ratio
- DRRX N/A
- MIRM N/A
- Revenue Growth
- DRRX 79.84
- MIRM 69.31
- 52 Week Low
- DRRX $0.48
- MIRM $33.45
- 52 Week High
- DRRX $1.74
- MIRM $54.23
- Technical
- Relative Strength Index (RSI)
- DRRX 58.38
- MIRM 53.95
- Support Level
- DRRX $0.60
- MIRM $49.39
- Resistance Level
- DRRX $0.67
- MIRM $51.93
- Average True Range (ATR)
- DRRX 0.06
- MIRM 1.53
- MACD
- DRRX 0.01
- MIRM -0.27
- Stochastic Oscillator
- DRRX 45.06
- MIRM 31.40
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.